Evident Vascular moves toward FDA clearance with Series B financing

Evident Vascular has added new investors at the close of a Series B financing round to support the launch of the firm’s AI-powered intravascular ultrasound (IVUS) platform in the U.S.

The San Jose, CA-based company did not disclose the amount raised in the funding round but said new investor Shangbay Capital and two undisclosed multinational strategics contributed, joining founding investor Vensana Capital.

The funding adds to the $35 million raised in 2023. Evident plans to use it to accelerate the development of its IVUS technology designed for vascular imaging for peripheral and coronary interventions, as well as support its efforts to secure U.S. Food and Drug Administration 510(k) clearance, the firm said.